PMID- 16465195
OWN - NLM
STAT- MEDLINE
DCOM- 20060323
LR  - 20220311
IS  - 0007-0920 (Print)
IS  - 1532-1827 (Electronic)
IS  - 0007-0920 (Linking)
VI  - 94
IP  - 4
DP  - 2006 Feb 27
TI  - Comprehensive profiling and localisation of the matrix metalloproteinases in 
      urothelial carcinoma.
PG  - 569-77
AB  - The matrix metalloproteinases (MMPs) are endopeptidases which break down the 
      extracellular matrix and regulate cytokine and growth factor activity. Several 
      MMPs have been implicated in the promotion of invasion and metastasis in a broad 
      range of tumours including urothelial carcinoma. In this study, RNA from 132 
      normal bladder and urothelial carcinoma specimens was profiled for each of the 24 
      human MMPs, the four endogenous tissue inhibitors of MMPs (TIMPs) and several key 
      growth factors and their receptors using quantitative real time RT-PCR. Laser 
      capture microdissection (LCM) of RNA from 22 tumour and 11 normal frozen sections 
      was performed allowing accurate RNA extraction from either stromal or epithelial 
      compartments. This study confirms the over expression in bladder tumour tissue of 
      well-documented MMPs and highlights a range of MMPs which have not previously 
      been implicated in the development of urothelial cancer. In summary, MMP-2, 
      MT1-MMP and the previously unreported MMP-28 were very highly expressed in tumour 
      samples while MMPs 1, 7, 9, 11, 15, 19 and 23 were highly expressed. There was a 
      significant positive correlation between transcript expression and tumour grade 
      for MMPs 1, 2, 8, 10, 11, 12, 13, 14, 15 and 28 (P < 0.001). At the same 
      confidence interval, TIMP-1 and TIMP-3 also correlated with increasing tumour 
      grade. LCM revealed that most highly expressed MMPs are located primarily within 
      the stromal compartment except MMP-13 which localised to the epithelial 
      compartment. This work forms the basis for further functional studies, which will 
      help to confirm the MMPs as potential diagnostic and therapeutic targets in early 
      bladder cancer.
FAU - Wallard, M J
AU  - Wallard MJ
AD  - Department of Oncology, Hutchison MRC Research Centre, University of Cambridge, 
      Hills Road, Cambridge CB2 2XZ, UK. mjw38@cam.ac.uk
FAU - Pennington, C J
AU  - Pennington CJ
FAU - Veerakumarasivam, A
AU  - Veerakumarasivam A
FAU - Burtt, G
AU  - Burtt G
FAU - Mills, I G
AU  - Mills IG
FAU - Warren, A
AU  - Warren A
FAU - Leung, H Y
AU  - Leung HY
FAU - Murphy, G
AU  - Murphy G
FAU - Edwards, D R
AU  - Edwards DR
FAU - Neal, D E
AU  - Neal DE
FAU - Kelly, J D
AU  - Kelly JD
LA  - eng
GR  - G0100250/MRC_/Medical Research Council/United Kingdom
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Br J Cancer
JT  - British journal of cancer
JID - 0370635
RN  - 0 (Biomarkers, Tumor)
RN  - EC 3.4.24.- (Matrix Metalloproteinases)
SB  - IM
MH  - Biomarkers, Tumor/*analysis
MH  - *Gene Expression Profiling
MH  - Humans
MH  - Matrix Metalloproteinases/*analysis/*biosynthesis/metabolism
MH  - Reverse Transcriptase Polymerase Chain Reaction
MH  - Sensitivity and Specificity
MH  - Tissue Distribution
MH  - Urinary Bladder Neoplasms/*enzymology/pathology
PMC - PMC2361180
EDAT- 2006/02/09 09:00
MHDA- 2006/03/24 09:00
PMCR- 2007/02/27
CRDT- 2006/02/09 09:00
PHST- 2006/02/09 09:00 [pubmed]
PHST- 2006/03/24 09:00 [medline]
PHST- 2006/02/09 09:00 [entrez]
PHST- 2007/02/27 00:00 [pmc-release]
AID - 6602931 [pii]
AID - 10.1038/sj.bjc.6602931 [doi]
PST - ppublish
SO  - Br J Cancer. 2006 Feb 27;94(4):569-77. doi: 10.1038/sj.bjc.6602931.